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drawn recently to experimental noise as a 
source of false-positive outcomes (Schna-
bel, 2008). It is possible that the Cerletti et 
al. (2008) study may, likewise, have been 
impacted by the problem of experimental 
noise.
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tridge raises two issues regarding our 
recent study investigating the stem cell 
properties of FACS-purified skeletal 
muscle precursors (SMPs) (Cerletti et al., 
2008). First, he challenges our conclu-
sion that SMPs represent a distinct myo-
genic cell population, and second, he 
questions our physiological assessment 
of the SMP-engrafted muscles of dystro-
phic mdx mice. However, as elaborated 
below, his point regarding the novelty of 
our cell isolation strategy is inaccurate, 
and more importantly, his reanalysis of 
our functional data uses inappropriate 
statistical methods that lead him to an 
erroneous conclusion.
First, Dr. Partridge argues that SMPs 
are not a unique myogenic cell population 
because (1) SMPs share phenotypic mark-
ers with muscle satellite cells, and (2) a pre-
vious publication (Montarras et al., 2005), 
which he coauthored, isolated a similar 
population of cells using gene-targeted 
Pax3-GFP reporter mice and another cell-
surface marker (CD34 expression).
We agree that SMPs have properties 
similar to Pax3-GFP+ muscle satellite cells 
and properly credit this work in our paper 
(Cerletti et al., 2008, p. 42). However, Dr. 
Partridge seems to disregard direct evi-
dence presented in our study that SMPs 
are a distinct subset of muscle satellite 
cells. We showed that most SMPs do 
express the canonical satellite cell marker 
Pax7, but that SMP markers (β1-integrin 
and CXCR4) are expressed by only ~80% 
of Pax7+ cells. Thus, we conclude that 
SMPs are a subpopulation of satellite 
cells, which unlike Pax3-GFP+ cells (Mon-
tarras et al., 2005) do not require special-
ized transgenic mouse strains for their 
isolation. More importantly, however, our 
work rigorously demonstrates distinctive 
functional and physiological properties 
of SMPs (Cerletti et al., 2008; Sherwood 
et al., 2004), an essential step in the 
effective characterization of any stem or 
progenitor cell population (Wagers and 
Weissman, 2004). In particular, we have 
shown that SMPs are the only subset of 
myofiber-associated cells that exhibits 
clonal myogenesis in vitro and a robust 
myogenic contribution in vivo. Our more 
recent experiments using intramuscular 
transplantation of single GFP+ SMPs fur-
ther demonstrate that ~50% of muscles 
transplanted with a single SMP exhibit 
detectable myofiber engraftment (n = 10 
muscles, M.C. and A.W., unpublished 
data). Given that previous studies indicate 
that 99% of myogenic donor cells per-
ish almost immediately upon transplant 
(Beauchamp et al., 1999), these data 
clearly indicate that selection for SMP 
markers yields a unique, highly purified 
population of cells that is well suited to in 
vivo cell therapy.
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tridge relates to our conclusion that high-
level in vivo engraftment of myofibers by 
donor SMPs results in improved physi-
ological function in recipient muscles. 
His challenge is based largely on the fact 
that we presented our data in a chart that 
correlated muscle engraftment level with 
the fold difference in contractile activity of 
SMP-treated versus mock-treated con-
tralateral muscles in the same animal (see 
Figure 5, Cerletti et al., 2008). We main-
tain that this is an appropriate method of 
analysis because the comparison of SMP-
treated versus mock-treated muscles in 
the same mouse accounts for variability 
in dystrophic disease and in engraftment 
efficiency in individual mdx recipients. In 
fact, clinical trials for myoblast transplan-
tation and for exon skipping use similar 
comparisons to assess treatment efficacy 
(http://www.clinicaltrials.gov/, reviewed 
in Cossu and Sampaolesi, 2007). In any 
case, we also provided the same data in 
raw form in the Supplemental Data of our 
paper (Table S1). 
Using the data in our Table S1 (Cerletti 
et al., 2008), Dr. Partridge has reanalyzed 
our results and comes to the conclusion 
that the only reason our SMP-treated 
muscles showed improvement is that 
they were compared to contralateral 
muscles that were particularly weak. This 
conclusion is based on replotting of our 
data using a linear regression model and 
on parametric correlation tests, which 
Dr. Partridge states “fall short of statisti-
cal significance at 5%” (in fact, the actual 
values are p = 0.055 and p = 0.056, using 
Pearson’s product-moment correlation, 
for the specific peak force and the inte-
grated area under the curve, respec-
tively). However, as discussed below, Dr. 
Partridge’s use of linear regression and 
parametric statistics to re-evaluate our 
data is incorrect.
To address the concerns raised by Dr. 
Partridge in his Correspondence, we sub-
mitted our raw data to statistics experts 
in the Department of Biostatistics and 
Computational Biology at the Dana-Far-
ber Cancer Institute, and they performed 
an independent analysis. This analysis 
determined that the data are not ade-
quately represented by the linear regres-
sion model that Dr. Partridge uses. The 
linear regression model requires that the 
data being analyzed show a linear rela-
tionship and a normal distribution; yet our 
data meet neither of these requirements. 
Instead, our data are more appropriately 
represented by a nonlinear smoothing 
Lowess fit (locally weighted polynomial 
regression) (Cleveland, 1979; Cleveland 
and Devlin, 1988), shown here in Figure 
S1 available online. In addition, because 
the data are not normally distributed and 
have a small sample size, they should be 
analyzed using rank-based nonparametric 
statistics, as in Figure S1 shown here, to 
more robustly assess correlation and dif-
ferences between groups.
In Figure S1, we replot our raw data 
(Table S1, Cerletti et al., 2008), showing 
the average change in peak force and 
integrated area under the curve (AUC), 
and separately analyze the SMP-treated 
(red triangles) and mock-treated (black 
diamonds) animals. This analysis con-
firms a clear and significant correlation 
between the level of engraftment by 
GFP+ SMPs and improvement in con-
tractile force of the SMP-treated muscles 
(Figures S1A and S1B; p = 0.01 for each 
plot by Spearman’s rank test). Contrary 
to Dr. Partridge’s assertion, this corre-
lation is not dependent on the strength 
of the mock-transplanted contralateral 
muscles, which do not show a correla-
tion with engraftment rate (p = 0.17 and p 
= 0.14 by Spearman’s rank test for peak 
force or AUC, respectively).
In a further test of Dr. Partridge’s 
claim, we also performed subset analy-
sis, comparing data from animals that 
showed significant functional improve-
ment in their engrafted muscles (i.e., ani-
mals exhibiting a difference in specific 
peak force of >1-fold when comparing their SMP-treated and mock-treated 
muscles) to data obtained from analysis 
of a separate cohort of untreated mdx 
mice. We found no significant differ-
ence in peak force production between 
the mock-treated muscles (n = 10, 
median = 12.4, range 1.6–39.1 mN/mm2) 
and untreated mdx control mice (n = 9, 
median = 5.4, range 2.4–28.9 mN/mm2; p 
= 0.11 by two-sided Wilcoxon rank-sum 
exact test). Thus, in our view, Dr. Par-
tridge is incorrect in his contention that 
the contralateral mock-treated muscles 
of the highly engrafted animals in our 
study were exceptionally weak and that 
the strength improvements we observed 
in highly engrafted muscles arose solely 
as a result of this weakness.
Furthermore, consistent with the con-
clusions of our publication, this subset 
analysis also confirmed that the SMP-
engrafted muscles in our study exhibited 
greater force production than both the 
contralateral mock-treated muscles and 
the untreated muscles of control mdx 
mice. In particular, muscles from SMP-
engrafted mice showed significantly 
greater force production (n = 10, median 
= 30, range 1.9–43.0 mN/mm2) than 
untreated mdx muscles (see above, p = 
0.004 by two-sided Wilcoxon rank-sum 
exact test). In addition, for SMP-treated 
muscles versus mock-treated muscles (n 
= 10), the median fold change in average 
peak force was 1.8 (range, 1.1- to 5.5-fold) 
and was significantly greater than 1 (p = 
0.009) by a one-sided Student’s t test. 
As highlighted in the Correspondence by 
Dr. Partridge, one highly engrafted ani-
mal did show a surprisingly large differ-
ence in force generation (~5-fold greater); 
however, we note that the median differ-
ence in force production between SMP-
engrafted and mock-treated muscles in 
this group of animals was more modest 
(1.8-fold).
In conclusion, although we appreci-
ate the close consideration of our paper 
by Dr. Partridge, we show here that his 
reanalysis of our data is not based on 
proper statistical methods and therefore 
does not in fact challenge the original 
interpretations of our paper. The points 
he raises do not alter the main conclu-
sions of our work, namely, that FACS-
purified SMPs are a prospectively iso-
latable subset of canonically defined Cell 135, Dmuscle satellite cells and exhibit robust 
engraftment to generate both functional 
muscle fibers and undifferentiated satel-
lite cells upon intramuscular transplant. 
These properties suggest that SMPs 
represent a therapeutically promising 
stem cell population for immediate repair 
of dystrophin-deficient muscle as well 
as an enduring source of regenerative 
cells that can be recruited in response to 
future muscle injuries.
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